<DOC>
	<DOCNO>NCT01895205</DOCNO>
	<brief_summary>The primary purpose study get explorative information IV high single dose infusion iron isomaltoside 1000 compare RBC transfusion treatment severe PP-IDA evaluate physical fatigue</brief_summary>
	<brief_title>Treatment Women After Severe Postpartum Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . PPH &gt; 1000 mL 2 . Hb ≥ 5.5 ≤ 8.0 g/dL ( ≥ 3.5 ≤ 5.0 mmol/L ) 3 . Willingness participate sign informed consent form 1 . Women age &lt; 18 year 2 . Multiple births 3 . Peripartum RBC transfusion 4 . Known iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) 5 . Known hypersensitivity parenteral iron excipients investigational drug product 6 . Women history active asthma within last 5 year history multiple allergy 7 . Known decompensated liver cirrhosis active hepatitis 8 . Women HELLP ( Haemolysis Elevated Liver enzymes Low Platelet count ) syndrome ( define accord `` Dansk Selskab Obstetrik og Gynækologi guideline '' ) 9 . Active acute infection assess clinical judgement 10 . Rheumatoid arthritis symptom sign active joint inflammation 11 . History anaemia cause e. g. thalassemia , hypersplenism haemolytic anaemia ( know haematologic disorder iron deficiency ) 12 . Not able read , speak understand Danish language 13 . Participation clinical study study drug pass 5 halflives prior baseline 14 . Any medical condition , opinion Investigator , may cause patient unsuitable completion study place patient potential risk study . For example , malignancy , uncontrolled hypertension , unstable ischaemic heart disease uncontrolled diabetes mellitus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>